Amlodipine: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) m (Changed protection level for "Amlodipine" ([Edit=Allow only autoconfirmed users] (expires 14:04, 19 March 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 14:04, 19 March 2014 (UTC)))) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Amlodipine}} | |||
{{CMG}}; {{AE}} | |||
'''''For patient information about Amlodipine, click [[Amlodipine (patient information)|here]].''''' | |||
{{SB}} | |||
NORVASC<sup>®</sup>, AMLODIPINE<sup>®</sup>, AMLODIPINE BESYLATE<sup>®</sup>. | |||
< | |||
== | ==Overview== | ||
[[ | '''Amlodipine''' ('''Norvasc''' (Pfizer) and generics) (as [[besylate]], [[mesylate]] or [[maleate]]) is a long-acting [[dihydropyridine]]-type (DHP) [[calcium channel blocker]] used [[antihypertensive|to lower blood pressure]] and to treat [[angina pectoris|anginal chest pain]]. Like other calcium channel blockers, amlodipine lowers blood pressure by relaxing [[Artery|arterial]] [[smooth muscle]]s, which decreases [[total peripheral resistance]] and therefore reduces [[blood pressure]]. In angina, amlodipine increases blood flow to the [[Cardiac muscle|heart muscle]] (although DHP-class calcium channel blockers are more selective for arteries than the muscular tissue of the heart (myocardium), as the calcium ion channels of the heart are not of the dihydropyridine-type). | ||
==Category== | |||
[[Dihydropyridine]] [[calium channel blocker]]. | |||
[[ | ==FDA Package Insert== | ||
[[ | |||
[[ | |||
[[ | |||
[[ | |||
[[ | |||
[[ | |||
[[ | |||
[[ | |||
== | ====NORVASC<sup>®</sup>=== | ||
< | |||
< | |||
''' [[Amlodipine indications and usage|Indications and Usage]]''' | |||
[ | '''| [[Amlodipine dosage and administration|Dosage and Administration]]''' | ||
'''| [[Amlodipine dosage forms and strengths|Dosage Forms and Strengths]]''' | |||
'''| [[Amlodipine contraindications|Contraindications]]''' | |||
[ | '''| [[Amlodipine warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[Amlodipine adverse reactions|Adverse Reactions]]''' | |||
'''| [[Amlodipine drug interactions|Drug Interactions]]''' | |||
[ | '''| [[Amlodipine use in specific populations|Use in Specific Populations]]''' | ||
'''| [[Amlodipine overdosage|Overdosage]]''' | |||
'''| [[Amlodipine description|Description]]''' | |||
'''| [[Amlodipine clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Amlodipine nonclinical toxicology|Nonclinical Toxicology]]''' | |||
'''| [[Amlodipine clinical studies|Clinical Studies]]''' | |||
'''| [[Amlodipine how supplied storage and handling|How Supplied/Storage and Handling]]''' | |||
[ | '''| [[Amlodipine patient counseling information|Patient Counseling Information]]''' | ||
'''| [[Amlodipine labels and packages|Labels and Packages]]''' | |||
[ | |||
[ | |||
[ | |||
== | ==Mechanism of Action== | ||
[[ | Amlodipine is a [[dihydropyridine]] [[calcium antagonist]] (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and [[nondihydropyridine]] binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative [[inotropic]] effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine. Within the physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect. | ||
[ | |||
Amlodipine is a peripheral arterial [[vasodilator]] that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure. | |||
The precise mechanisms by which amlodipine relieves [[angina]] have not been fully delineated, but are thought to include the following: | |||
'''Exertional Angina:''' In patients with exertional [[angina]], NORVASC reduces the total peripheral resistance ([[afterload]]) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise. | |||
'''Vasospastic Angina:''' NORVASC has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium [[epinephrine]], [[serotonin]], and [[thromboxane A2]] analog in experimental animal models and in human coronary vessels in vitro. This inhibition of coronary spasm is responsible for the effectiveness of NORVASC in vasospastic ([[Prinzmetal's]] or variant) angina.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NORVASC (AMLODIPINE BESYLATE) TABLET [CARDINAL HEALTH] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44e5ad27-e062-461a-bdf4-192d852fbc49#nlm42230-3 | publisher = | date = | accessdate = 6 March 2014 }}</ref>==References== | |||
{{Reflist|2}} | |||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 22:18, 6 March 2014
| Amlodipine |
|---|
| NORVASC®, AMLODIPINE®, AMLODIPINE BESYLATE® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Dosage Forms and Strengths |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| Clinical Studies |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Amlodipine |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
For patient information about Amlodipine, click here.
Synonyms / Brand Names: NORVASC®, AMLODIPINE®, AMLODIPINE BESYLATE®.
Overview
Amlodipine (Norvasc (Pfizer) and generics) (as besylate, mesylate or maleate) is a long-acting dihydropyridine-type (DHP) calcium channel blocker used to lower blood pressure and to treat anginal chest pain. Like other calcium channel blockers, amlodipine lowers blood pressure by relaxing arterial smooth muscles, which decreases total peripheral resistance and therefore reduces blood pressure. In angina, amlodipine increases blood flow to the heart muscle (although DHP-class calcium channel blockers are more selective for arteries than the muscular tissue of the heart (myocardium), as the calcium ion channels of the heart are not of the dihydropyridine-type).
Category
Dihydropyridine calium channel blocker.
FDA Package Insert
=NORVASC®
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine. Within the physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect.
Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.
The precise mechanisms by which amlodipine relieves angina have not been fully delineated, but are thought to include the following:
Exertional Angina: In patients with exertional angina, NORVASC reduces the total peripheral resistance (afterload) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise.
Vasospastic Angina: NORVASC has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels in vitro. This inhibition of coronary spasm is responsible for the effectiveness of NORVASC in vasospastic (Prinzmetal's or variant) angina.[1]==References==
- ↑ "NORVASC (AMLODIPINE BESYLATE) TABLET [CARDINAL HEALTH]". Retrieved 6 March 2014.